Adam Davidson, CEO of Trident Royalties, discusses offtake milestones and catalysts to boost FY24. Watch the video here.

Less Ads, More Data, More Tools Register for FREE
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPOView Video
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plantView Video

Latest Share Chat

Pin to quick picksSynairgen Share News (SNG)

Share Price Information for Synairgen (SNG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 6.20
Bid: 5.32
Ask: 6.50
Change: 0.00 (0.00%)
Spread: 1.18 (22.18%)
Open: 6.20
High: 6.20
Low: 6.20
Prev. Close: 6.20
SNG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK TRADING UPDATE SUMMARY: Synairgen Starts Covid-19 Treatment Trial

Tue, 31st Mar 2020 12:21

(Alliance News) - The following is a round-up of updates by UK companies on the impact of the Covid-19 pandemic, issued on Tuesday and not separately reported by Alliance News:

----------

Synairgen PLC - respiratory drug discovery - Commences dosing of patients in trial of SNG001 - an inhaled formulation of interferon-beta-1a - in Covid-19 patients. The first patient was dosed at University Hospital Southampton. "A successful outcome from this trial in COVID-19 patients would be a very important step towards a major breakthrough in the fight against this coronavirus pandemic," said Chief Executive Officer Richard Marsden.

----------

Nichols PLC - soft drinks - Cancels final dividend for 2019 of 28.0 pence per share. Unable to give financial guidance for 2020, but expects significant impact on group's performance. Reviewing arrangements for annual general meeting.

----------

Costain Group PLC - infrastructure construction and engineering - Will not pay a final dividend for 2019, pauses construction activities in London. Reports little change in demand for consultancy services to energy, defence and aviation, while critical services provision to highway, local authority clients and water utilities to continue.

----------

FIH Group PLC - specialist services group - Expects performance for year ended March 31 to be in line with market expectations, despite tough conditions. Reduces activity significantly at Momart and Portsmouth Harbour Ferry Co. Will not recommend final dividend payment, and has reduced board salaries by 30% for three months.

----------

Kape Technologies PLC - digital security and privacy software - Reports increased demand for products due to rise in remote and home working. On track to deliver adjusted earnings before interest, taxes, depreciation and amortisation of USD35 million to USD38 million in 2020, and revenue of USD120 million to USD123 million. For 2019, adjusted Ebitda was USD14.6 million and revenue USD66.1 million.

----------

Harvest Minerals Ltd - fertilizer - No impact yet on operations, but taken steps to prevent the spread of the infection. Expects 2019 results to be published late in the second quarter of 2020.

----------

Savannah Resources PLC - energy metals - Closes all offices and all field activities and reduces staff at Mutamba mineral sands project camp in Mozambique. However has continued environment impact assessment and mine plan for Mina do Barroso lithium project in Portugal, and pre-feasibility study data review for Mutamba.

----------

Parity Group PLC - staffing and consultancy - Delays publication of 2019 results in line with UK regulator's request, but says adjusted pretax profit to be in line with expectations. Unable to give accurate forecast for 2020, but expects revenue hit due to uncertainty in public sector.

----------

Toople PLC - telecom services - All staff in UK, Durban and Poland working remotely without disruption to any key business functions. Once UK government lockdown is lifted, will move all operations to Bishop's Stortford from Slough.

----------

TMT Investments PLC - venture capital - No disruptions to company's activities, and majority of portfolio firms well positioned to withstand impact of Covid-19. However, will take up selective investment approach, meaning no significant investments to be made in coming months. In addition, 2019 results publication delayed.

----------

Xpediator PLC - freight management services - Expects to publish 2019 results in April, with revenue up 19% to GBP212 million and pretax profit above GBP5.0 million. Trading in the first three months of 2020 in line with expectations, but unable to give longer-term guidance for the year.

----------

Catenae Innovation PLC - digital media - Delays release of results, for year ended September 2019, to June 30 at latest. Expects to report loss of GBP789,565 on turnover of GBP102,549.

----------

Hardide PLC - surface coating technology - Revenue for six months ended March 31 to be 25% up from year before, as facilities in Oxfordshire, UK and Virginia, US continue operations, on strong demand from oil & gas customers.

----------

Marlowe PLC - safety and compliance services - Reports strong trading in second half ended March 31, despite challenging conditions in recent weeks. However, because of government restrictions preventing employees from accessing work sites, expects impact on performance in first quarter of new financial year.

----------

Quixant PLC - gaming and broadcast technology - Delays 2019 results to April 6, but reports 20% decline in revenue to USD92.3 million, and 41% drop in adjusted pretax profit to USD10.7 million, due to reduced demand for products. Suspends dividend payout and withdraws guidance for 2020 and beyond.

----------

Sabien Technology Group PLC - boiler-load optimisation controls - Furloughs all non-essential staff, and suspends all non-essential business functions. To continue work potential acquisition of Ptarmigan SA, with target completion within the second quarter.

----------

Appreciate Group PLC - gift cards and vouchers - Trading in 11 months to end of February in line with management expectations, but in order to preserve cash, will cancelling interim dividend payment and is reviewing bonuses. Closes all offices and fulfilment locations. To provide further update at end of April.

----------

Falanx Group Ltd - cyber security services - Reports strong trading in year ended Tuesday, expects revenue growth by 13% year-on-year to GBP5.9 million. Expects to still be able to operate effectively despite lockdowns and pandemic.

----------

Thalassa Holdings Ltd - investment holdings firm - Delays publication of 2019 results.

----------

Dewhurst PLC - electrical components manufacture - Closes operations at Dewhurst UK, but A&A and TMP to continue operations with reduced workforce. Withdraws guidance for future performance, and is reviewing dividend policy for year ending September 2020. Expects first-half results to February 29 to be GBP28 million, in line with year before.

----------

Power Metal Resources PLC - metals exploration and development - Delays final results publication to May 30 from original date of March 31. Conducts ongoing review of business operations to determine Covid-19 effect. Principal operations remain unaffected, including field work in Democratic Republic of Congo.

----------

Angle PLC - liquid biopsy - Ceases operations at Angle UK laboratories and offices. Withdraws guidance for future financial years, and plans to publish results for eight months to December 31 in May instead of April.

----------

Europa Oil & Gas Holdings PLC - UK & Ireland-focused energy development - Expects existing cash reserves to be sufficient to finance activity at Wressle field development project, ongoing farm-out activities, and reduced work programmes offshore Ireland and Morocco. However, has implemented cost -cutting measures including salary cuts, and cancellation of non-core contracts.

----------

Northern Bear PLC - building services - Expects operating profit for year ended March 31 to be between GBP2.2 million and GBP2.3 million, down from GBP3.2 million the year before. Renews existing GBP3.5 million revolving credit facility with Yorkshire Bank. Majority of businesses see construction sites close.

----------

SpaceandPeople PLC - retail licensing space marketing - Furloughs majority of staff in UK offices with effect from April 1, with similar scheme implemented in Germany. All premises in UK, Germany and India closed, and volume of business transacted has decreased significantly. Cancels proposed dividend, and cuts non-essential spend.

----------

By Dayo Laniyan; dayolaniyan@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
18 Apr 2019 11:52

Synairgen Non-Executive Director Paul Clegg To Retire In June

LONDON (Alliance News) - Synairgen PLC on Thursday said Non-Executive Director Paul Clegg will retire from the company's board after the company's annual general meeting on June Buchanan,

Read more
14 Mar 2019 14:47

Synairgen broadens SNG001 trial after committee review

(Sharecast News) - Respiratory drug discovery and development company Synairgen announced on Thursday that its data safety monitoring committee had completed its planned safety review of the second part of the phase 2 clinical trial of its inhaled interferon-beta (IFN-beta) therapeutic candidate, SNG001, in patients with chronic obstructive pulmonary disease (COPD).

Read more
14 Mar 2019 11:37

Synairgen Gets Positive Safety Review Of SNG001 Candidate

LONDON (Alliance News) - Synairgen PLC on Thursday said the Data Safety Monitoring Committee has completed its planned safety review of a clinical trial of therapeutic candidate, SNG001.The

Read more
25 Feb 2019 11:41

Synairgen Swings To Annual Loss As Costs Rise And Revenue Drops

LONDON (Alliance News) - Synairgen PLC on Monday said it swung to an annual loss due to higher research costs and the lack of a non-recurring GBP5 million payment from Pharmaxis received in 2018,

Read more
22 Oct 2018 11:53

Synairgen Begins Dosing For Next Stage Of SNG001 Clinical Trial

LONDON (Alliance News) - Synairgen PLC said Monday it has begun dosing for the next part of its SNG001 chronic obstructive pulmonary disease treatment trial.The respiratory drug discovery a

Read more
22 Oct 2018 09:20

Synairgen begins second part of SNG001 Phase II trial

(Sharecast News) - Respiratory drug discovery and development company Synairgen has started the second part of its Phase II clinical trial for its wholly-owned inhaled interferon-beta (IFN-beta) therapeutic candidate, SNG001, in patients with chronic obstructive pulmonary disease (COPD), it announced on Monday.

Read more
25 Sep 2018 13:48

Synairgen Fundraises To Progress Clinical Tests As Interim Loss Widens (ALLISS)

LONDON (Alliance News) - Synairgen PLC on Tuesday announced fundraising to cover the clinical trials of its wholly-owned antiviral therapy SNG001 after its loss widened in the first half of drug a

Read more
15 Mar 2018 12:57

Synairgen Swings To Profit On Lump Sum Payment As Pipeline Progresses

LONDON (Alliance News) - Respiratory drug development firm Synairgen PLC swung to a full year profit Thursday after a lump sum payment from a collaboration partner offset and

Read more
12 Oct 2016 09:52

Synairgen shares drop as AstraZeneca stops asthma drug study

(ShareCast News) - Synairgen's, the respiratory drug discovery and development company, hit the skids after its partner Astrazeneca announced that it has dropped its clinical trial for asthma drug AZD9412. AZD9412, which is a form of inhaled interferon beta, was investigated in an INEXAS trial in pa

Read more
22 Mar 2016 11:07

Synairgen Swings To Loss But Gets Good LOXL2 Trial Results

Read more
21 Mar 2016 16:06

Earnings, Trading Statements Calendar - Week Ahead

Read more
12 Nov 2015 11:35

DIRECTOR DEALINGS: Synairgen Directors Snap Up 163,000 Shares

Read more
16 Sep 2015 13:03

Synairgen's profit dips, R and D expenditure reduced

(ShareCast News) - Synairgen has posted an after tax loss of £0.91m for the six months to 30 June, down from a profit of £1.90m in the same period last year. The respiratory drug discovery and development company announced its unaudited interim results for the six months ended 30 June 2015. Researc

Read more
16 Sep 2015 09:50

Synairgen Swings To Loss As AstraZeneca Revenue Bump Doesn't Repeat

Read more
5 Aug 2015 10:21

Synairgen shares surge on research collaboration deal

(ShareCast News) - Synairgen surged after announcing that it has entered into a research collaboration deal with Australian pharmaceutical company Pharmaxis. The respiratory drug discovery and development company said they will develop a selective inhibitor to the lysyl oxidase type 2 enzyme to trea

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.